Page 167 - Read Online

Page 14 of 29 Dastidar et al. Vessel Plus 2020;4:14 I http://dx.doi.org/10.20517/2574-1209.2019.36

[130] [131] [132] [133] [134] [135] [136] [137] [138]

2016 2019 2018 2013 2016 2018 2019 2018 2014

Ex vivo: drug-resistant NSCLC Ex vivo: NCI-H23 cell line Clinical (open level phase II clinical trial): patients with locally advanced, inoperable, or metastatic pancreatic cancer Ex vivo: A549 cell line In vivo: tumour xenograft model using SD rats Ex vivo: A549 cell line In vivo: A549 xenograft model in nude mice Ex vivo: human umbilical vein endothelial cells Ex vivo: different breast cancer cell lines like MDA-MB-231, MDA-MB-468, M

kinase whereas paclitaxel arrests cancer Lapatinib inhibits EGFR and HER2 tyrosine Ex vivo: 4T1 murine mammary cell cells at G2/M phase Afatinib inhibits EGFR and HER2 tyrosine kinase whereas paclitaxel arrests cancer cells at G2/M phase Erlotinib inhibits EGFR tyrosine kinase whereas paclitaxel arrests cancer cells at G2/M phase Erlotinib inhibits EGFR tyrosine kinase whereas gemcitabine kills cancer cells Erlotinib and DOX were released

Afatinib was loaded in stearic acid-based solid lipid nanoparticles. This nanoparticle and paclitaxel were loaded in polylactide- coglycolide-based porous microspheres Both erlotinib and paclitaxel were encapsulated in glyceryl monostearate nanoparticles, which was coated with a PEGylated polymeric layer Erlotinib (100 mg/d, orally), Gemcitabine (1000 mg/m 2 , i.v. infusion) pH-sensitive charge conversion nanocarrier. DOX was loaded in amino

Liposome containing erlotinib in PLGA shell acid (PHCL), a pH triggered charge-controllable and redox responsive polymer [Figure 4] [105] .

Paclitaxel Paclitaxel Paclitaxel Gemcitabine DOX Not applicable Not applicable Paclitaxel Cisplatin BJ: Normal human fibroblasts cell line; SD: sprague dawley; PLGA: poly(lactic-co-glycolic acid)

Lapatinib Afatinib Erlotinib Erlotinib Erlotinib Thalidomide Everolimus Everolimus Rapamycin

Epidermal growth factor Androgen receptor mTOR